ECSP21030066A - 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 - Google Patents

2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8

Info

Publication number
ECSP21030066A
ECSP21030066A ECSENADI202130066A ECDI202130066A ECSP21030066A EC SP21030066 A ECSP21030066 A EC SP21030066A EC SENADI202130066 A ECSENADI202130066 A EC SENADI202130066A EC DI202130066 A ECDI202130066 A EC DI202130066A EC SP21030066 A ECSP21030066 A EC SP21030066A
Authority
EC
Ecuador
Prior art keywords
disorders
inhibitors
nicotinamidas
heteroaril
amino
Prior art date
Application number
ECSENADI202130066A
Other languages
English (en)
Inventor
Anthony Ginnetti
Harry Chobanian
Deodial Guy Guiadeen
Michael Breslin
Shawn Stachel
Jian Liu
Jason Cox
Mark Layton
Zhe Wu
Ashok Arasappan
Hong Liu
Christopher James Bungard
Kristen Jones
Linda Suen-Lai
Ian Bell
James Perkins
Christopher Burgey
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP21030066A publication Critical patent/ECSP21030066A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Los novedosos compuestos de la Fórmula estructural (I), y sus sales farmacéuticamente aceptables, son inhibidores de la actividad de los canales Nav1.8 y pueden ser útiles en el tratamiento, prevención, manejo, mejora, control y supresión de enfermedades mediadas por la actividad de los canales Nav1.8. Los compuestos de la presente invención pueden ser útiles en el tratamiento, prevención o manejo de trastornos de dolor, trastornos de tos, trastornos de picazón aguda y trastornos de picazón crónica. (Conforme la formula expuesta en el resumen de la memoria técnica.)
ECSENADI202130066A 2018-11-02 2021-04-27 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 ECSP21030066A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862754742P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
ECSP21030066A true ECSP21030066A (es) 2021-05-31

Family

ID=68655658

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202130066A ECSP21030066A (es) 2018-11-02 2021-04-27 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8

Country Status (28)

Country Link
US (4) US11377438B2 (es)
EP (1) EP3873893A1 (es)
JP (1) JP7288051B2 (es)
KR (3) KR102860523B1 (es)
CN (1) CN113272293B (es)
AR (1) AR116939A1 (es)
AU (2) AU2019372057A1 (es)
BR (2) BR112021008524A8 (es)
CA (1) CA3117927A1 (es)
CL (1) CL2021001078A1 (es)
CO (1) CO2021005553A2 (es)
CR (1) CR20210209A (es)
DO (1) DOP2021000082A (es)
EA (1) EA202191177A1 (es)
EC (1) ECSP21030066A (es)
GE (2) GEAP202315648A (es)
IL (1) IL282468B1 (es)
JO (1) JOP20210097B1 (es)
MA (1) MA54076A (es)
MX (1) MX2021005154A (es)
MY (1) MY197128A (es)
NI (1) NI202100029A (es)
PE (1) PE20211693A1 (es)
SG (1) SG11202104326TA (es)
TW (1) TWI784207B (es)
UA (1) UA130578C2 (es)
WO (1) WO2020092667A1 (es)
ZA (1) ZA202102628B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7676308B2 (ja) 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
EP3898616B1 (en) * 2018-12-20 2024-10-02 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US12540129B2 (en) 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
JP2023530319A (ja) * 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド
GEP20257750B (en) 2020-06-17 2025-03-25 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
EP4174069A4 (en) * 2020-07-03 2024-07-10 Wuhan LL Science and Technology Development Co., Ltd. HETEROCYCLIC COMPOUND AND ASSOCIATED USE
WO2022121805A1 (zh) * 2020-12-07 2022-06-16 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
CN112457294B (zh) * 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
MX2023013147A (es) * 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
SI4347031T1 (sl) * 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
JP2024520643A (ja) * 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
MA64856B1 (fr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide
WO2022256660A1 (en) * 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
JP2024520646A (ja) * 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体
TW202317520A (zh) 2021-06-15 2023-05-01 德商歌林達有限公司 經取代之吡唑醯胺
JP7773801B2 (ja) * 2021-06-25 2025-11-20 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｋｉｆ１８ａ阻害剤としての化合物
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
UY39882A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
EP4405347A1 (en) 2021-09-24 2024-07-31 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
EP4472966A4 (en) * 2022-02-04 2026-01-14 Latigo Biotherapeutics Inc SODIUM CHANNEL BLOCKING COMPOUNDS, THEIR DERIVATIVES AND METHODS OF USE
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
GEAP202516634A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
IL316433A (en) 2022-04-25 2024-12-01 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain
WO2023207949A1 (zh) * 2022-04-25 2023-11-02 中国科学院上海药物研究所 并环类化合物及其应用
CN119585260A (zh) * 2022-08-24 2025-03-07 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
JP2025529931A (ja) * 2022-08-28 2025-09-09 シャンハイ ホイルン ファーマシューティカル カンパニー リミテッド ナトリウムチャネル調節剤及びその応用
AU2023391870A1 (en) 2022-12-06 2025-06-05 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
EP4385979A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Multicyclic inhibitors of nav1.8
EP4385984A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Pyridine-n-oxides as inhibitors of nav1.8
AR131345A1 (es) 2022-12-14 2025-03-12 Gruenenthal Gmbh SULFOXIMINAS COMO INHIBIDORES DE NaV1.8
EP4385980A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Indazoles as inhibitors of nav1.8
WO2024137984A1 (en) * 2022-12-22 2024-06-27 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
AR131715A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS
PY2404093A (es) 2023-01-30 2024-10-03 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits
PY2404641A (es) 2023-01-30 2024-10-03 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS
EP4660184A1 (en) 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting hydroxamates, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
WO2024159285A1 (pt) 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
KR20250173577A (ko) * 2023-04-19 2025-12-10 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Nav1.8억제제 및 이의 제조 방법 및 용도
CN121100117A (zh) * 2023-05-16 2025-12-09 浙江海正药业股份有限公司 芳香酰胺类衍生物、其制备方法和其在医药上的应用
EP4727540A2 (en) * 2023-06-16 2026-04-22 Quantx Biosciences US, Inc. Fused bicyclic heterocyclic or hetero aryl amide compounds
CN119371405A (zh) * 2023-07-26 2025-01-28 上海闻耐医药科技有限公司 多取代吡咯烷类衍生物、其制备方法及用途
IL326238A (en) * 2023-08-01 2026-03-01 Latigo Biotherapeutics Inc Sodium channel blocking compounds, their derivatives and methods of using them
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
WO2025147116A1 (en) * 2024-01-05 2025-07-10 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6431779A (en) * 1987-07-28 1989-02-02 Hokuriku Pharmaceutical Pyrazine derivative
US8202861B2 (en) 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
WO2006016316A1 (en) 2004-08-11 2006-02-16 Koninklijke Philips Electronics N.V. Conference system with quality information
US7767680B2 (en) * 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
CA2648202A1 (en) * 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
JP2010116389A (ja) 2008-10-17 2010-05-27 Bayer Cropscience Ag 殺虫性アリールピロリジン類
CA2702101A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
CN101883760A (zh) 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的杂芳基酰胺类
AU2008310661A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
AU2009304508A1 (en) * 2008-10-17 2010-04-22 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2246335A1 (de) 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schädlingsbekämpfungsmittel
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
MX2012009561A (es) * 2010-02-17 2012-11-23 Amgen Inc Carboxamidas como inhibidores de canales de sodio dependientes del voltaje.
US8703768B2 (en) * 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
EP2630122B1 (en) * 2010-10-18 2016-11-30 RaQualia Pharma Inc Arylamide derivatives as ttx-s blockers
CN103429571A (zh) 2010-12-22 2013-12-04 普渡制药公司 作为钠通道阻断剂的取代吡啶
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
ES2602140T3 (es) * 2011-06-27 2017-02-17 Newron Pharmaceuticals S.P.A. Derivados de arilalquilaminocarboxamida fluorados
EA023375B1 (ru) 2011-10-26 2016-05-31 Пфайзер Лимитед Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2914597B1 (en) 2012-10-31 2017-12-06 RaQualia Pharma Inc Pyrazolopyridine derivatives as ttx-s blockers
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
AU2014212431B2 (en) 2013-01-31 2018-04-05 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
CA2913785C (en) 2013-06-25 2021-08-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
ES2654393T3 (es) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamidas como moduladores de los canales de sodio
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
RU2743074C2 (ru) * 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
JP2017214290A (ja) * 2014-09-12 2017-12-07 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物
JP6431779B2 (ja) 2015-01-30 2018-11-28 日立オートモティブシステムズ株式会社 車載制御装置および車載制御装置の製造方法
KR101844984B1 (ko) 2016-05-31 2018-04-03 한림대학교 산학협력단 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
GB201615622D0 (en) * 2016-09-14 2016-10-26 Syngenta Participations Ag Improvements in or relating to organic compounds
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
SG11202000230VA (en) * 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels

Also Published As

Publication number Publication date
TW202031643A (zh) 2020-09-01
CN113272293A (zh) 2021-08-17
MA54076A (fr) 2022-02-09
NI202100029A (es) 2021-08-13
MX2021005154A (es) 2021-07-15
BR112021008524A2 (pt) 2021-08-03
GEAP202315648A (en) 2023-07-25
AU2022287562B2 (en) 2024-08-01
CL2021001078A1 (es) 2021-10-29
JOP20210097A1 (ar) 2023-01-30
ZA202102628B (en) 2023-10-25
CO2021005553A2 (es) 2021-07-30
CA3117927A1 (en) 2020-05-07
CR20210209A (es) 2021-05-20
PE20211693A1 (es) 2021-09-01
IL282468A (en) 2021-05-31
JP2022506146A (ja) 2022-01-17
US20250084064A1 (en) 2025-03-13
US20200140411A1 (en) 2020-05-07
AU2022287562A1 (en) 2023-02-02
WO2020092667A1 (en) 2020-05-07
KR102812202B1 (ko) 2025-05-23
EA202191177A1 (ru) 2021-07-28
DOP2021000082A (es) 2021-07-22
CN113272293B (zh) 2024-06-14
US12195445B2 (en) 2025-01-14
KR20240161226A (ko) 2024-11-12
BR122023020853A2 (pt) 2024-01-16
US20220289710A1 (en) 2022-09-15
UA130578C2 (uk) 2026-03-25
BR112021008524A8 (pt) 2023-02-07
EP3873893A1 (en) 2021-09-08
JOP20210097B1 (ar) 2024-12-22
TWI784207B (zh) 2022-11-21
AU2019372057A1 (en) 2021-05-27
MY197128A (en) 2023-05-26
KR20240161227A (ko) 2024-11-12
JP7288051B2 (ja) 2023-06-06
WO2020092667A8 (en) 2021-05-20
GEP20237568B (en) 2023-11-27
KR20210086687A (ko) 2021-07-08
AR116939A1 (es) 2021-06-30
US11377438B2 (en) 2022-07-05
SG11202104326TA (en) 2021-05-28
US20210387966A1 (en) 2021-12-16
IL282468B1 (en) 2026-02-01
KR102860523B1 (ko) 2025-09-16

Similar Documents

Publication Publication Date Title
ECSP21030066A (es) 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
CO2022018295A2 (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
CL2023003295A1 (es) Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CO2022016377A2 (es) Inhibidores de kras tricíclicos fusionados
MX2023013147A (es) Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
MX2021013356A (es) Tratamiento y prevencion de enfermedades metabolicas.
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
CO2021014223A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
SA522432999B1 (ar) C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
AR132459A1 (es) Inhibidores de kras de pirrolidina
AR132909A1 (es) Métodos de tratamiento de enfermedades inflamatorias
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos